Biosimilar innovation is transforming the Stelara Market 2026

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Stelara (Ustekinumab) Market During 2026–2030?

The market size for stelara (ustekinumab) has shown robust expansion over the past few years. This market is projected to expand from $11.85 million in 2025 to reach $12.54 million by 2026, exhibiting a compound annual growth rate (CAGR) of 5.9%. Factors contributing to this historical growth include the shortcomings of traditional immunosuppressants, an increasing incidence of autoimmune diseases, compelling clinical efficacy data, the practice of hospital-based biologic administration, and a persistent need for lasting remission.

The market size for stelara (ustekinumab) is projected to exhibit robust growth over the coming years. Its value is expected to reach $15.57 million by 2030, progressing at a compound annual growth rate (CAGR) of 5.5%. This anticipated expansion during the forecast period is attributable to an increase in inflammatory bowel disease cases, the broadening of biologic reimbursement coverage, patients’ preference for less frequent dosing, the influence of biosimilar competition, and advancements in biologic delivery devices. Significant trends identified for the forecast horizon include the rising utilization of targeted biologic therapies, an expansion of autoimmune disease indications, a transition toward long-term maintenance treatment, the increasing adoption of subcutaneous biologics, and a rise in home-based administration.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19935&type=smp

Which Economic Or Industry Drivers Are Impacting The Stelara (Ustekinumab) Market?

The stelara (ustekinumab) market is projected to expand due to the increasing prevalence of psoriasis patients. Psoriasis is an autoimmune disorder that chronically accelerates skin cell turnover, resulting in red, scaly patches on individuals. Several factors contribute to this rise in prevalence, including better diagnosis methods, environmental triggers, genetic predispositions, and an aging demographic. Stelara (ustekinumab) works by targeting and inhibiting interleukin-12 and interleukin-23, which assists psoriasis patients by effectively reducing inflammation and plaque formation, leading to improved skin clearance and sustained symptom management, thereby enhancing their quality of life. For instance, in August 2024, a report by the National Psoriasis Foundation (NPF) revealed that psoriasis affects approximately 3% of U.S. adults aged 20 and above, which translates to over 7 million individuals. Additionally, it is estimated that around 600,000 adults in the country have psoriasis but have not yet been diagnosed. Therefore, the growing number of psoriasis patients is expected to drive the growth of the stelara (ustekinumab) market.

How Are The Various Segments Of The Stelara (Ustekinumab) Market Categorized?

The stelara (ustekinumab) market covered in this report is segmented –

1) By Indication: Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Other Indications

2) By Route Of Administration: Subcutaneous Injection, Intravenous Infusion

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

4) By End User: Pediatric, Adult, Geriatric

What Trends Are Affecting The Expansion Of The Stelara (Ustekinumab) Market?

Leading companies operating within the stelara (ustekinumab) market are actively developing innovative products, including biosimilars to stelara, to offer a more cost-effective treatment option for patients experiencing chronic inflammatory conditions. Stelara biosimilars are biologically analogous medications created to mimic the therapeutic effects of Stelara (Ustekinumab) by targeting IL-12 and IL-23, specifically for treating autoimmune conditions such as psoriasis and psoriatic arthritis. For example, in October 2024, Accord BioPharma Inc., a US-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval of IMULDOSA (ustekinumab-srlf), which is a biosimilar to Johnson & Johnson’s STELARA (ustekinumab). IMULDOSA is distinguished by its broad range of indications, providing treatment for adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and ulcerative colitis. It also carries a distinct indication for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis and active psoriatic arthritis, demonstrating its versatility across different age groups. This extensive coverage positions IMULDOSA as a valuable alternative for managing various immune-mediated inflammatory diseases.

Which Major Firms Influence Developments In The Stelara (Ustekinumab) Market?

Major companies operating in the stelara (ustekinumab) market are Johnson & Johnson

Read the full stelara (ustekinumab) market report here:

https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-

What Are The Top-Performing Regions Within The Stelara (Ustekinumab) Market?

North America was the largest region in the stelara (ustekinumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Stelara (Ustekinumab) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19935&type=smp

Browse Through More Reports Similar to the Global Stelara (Ustekinumab) Market 2026, By The Business Research Company

Stevia Market Report 2026

https://www.thebusinessresearchcompany.com/report/stevia-global-market-report

Stearic Acid Market Report 2026

https://www.thebusinessresearchcompany.com/report/stearic-acid-global-market-report

Sarcoma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795